These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 32972499)

  • 21. Low regulatory T cell and high IL-17 mRNA expression in a mouse Graves' disease model.
    Yuan Q; Zhao Y; Zhu X; Liu X
    J Endocrinol Invest; 2017 Apr; 40(4):397-407. PubMed ID: 27822606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fingolimod Improves the Outcome of Experimental Graves' Disease and Associated Orbitopathy by Modulating the Autoimmune Response to the Thyroid-Stimulating Hormone Receptor.
    Plöhn S; Hose M; Schlüter A; Michel L; Diaz-Cano S; Hendgen-Cotta UB; Banga JP; Bechrakis NE; Hansen W; Eckstein A; Berchner-Pfannschmidt U
    Thyroid; 2019 Sep; 29(9):1286-1301. PubMed ID: 31237525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Analysis of costimulatory molecules (CD28-CTLA-4/B7) expression on chosen mononuclear cells in adolescents with Graves' disease during methimazole therapy].
    Bossowski A; Stasiak-Barmuta A; Urban M; Rinderle C
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2004; 10(2):93-101. PubMed ID: 15504312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperthyroid monkeys: a nonhuman primate model of experimental Graves' disease.
    Wang Y; Wu LP; Fu J; Lv HJ; Guan XY; Xu L; Chen P; Gao CQ; Hou P; Ji MJ; Shi BY
    J Endocrinol; 2013 Dec; 219(3):183-93. PubMed ID: 24029729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody to gp39, the ligand for CD40 significantly inhibits the humoral response from Graves' thyroid tissues xenografted into severe combined immunodeficient (SCID) mice.
    Resetkova E; Kawai K; Enomoto T; Arreaza G; Togun R; Foy TM; Noelle RJ; Volpé R
    Thyroid; 1996 Aug; 6(4):267-73. PubMed ID: 8875745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease.
    Yamano Y; Takamatsu J; Sakane S; Hirai K; Kuma K; Ohsawa N
    Thyroid; 1999 Aug; 9(8):769-73. PubMed ID: 10482368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
    Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
    Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD8+CD122+ T cells, a newly identified regulatory T subset, negatively regulate Graves' hyperthyroidism in a murine model.
    Saitoh O; Abiru N; Nakahara M; Nagayama Y
    Endocrinology; 2007 Dec; 148(12):6040-6. PubMed ID: 17823258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of Jiakangning Capsule on Thyroid Function and Akt/mTOR Signal Pathway of Graves' Disease Mice: an Experimental Study].
    Li QM; Wei JP; Li M; Meng SH
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Sep; 35(9):1119-24. PubMed ID: 26591370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Graves' disease: effects of the administration of L-thyroxine associated with methimazole as a single daily dose.
    Perozim LM; Lima N; Knobel M; Cavaliere H; Medeiros-Neto G
    Eur J Med; 1993 Feb; 2(2):70-4. PubMed ID: 8258020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Graves' disease: diagnostic and therapeutic challenges (multimedia activity).
    Kahaly GJ; Grebe SK; Lupo MA; McDonald N; Sipos JA
    Am J Med; 2011 Jun; 124(6):S2-3. PubMed ID: 21605717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Relationship between OX40/4-1 BB (CD134/CD137) costimulatory molecules expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves' disease].
    Bossowski A; Stasiak-Barmuta A; Urban M; Rinderle C
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2005; 11(3):133-40. PubMed ID: 16232366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of intercellular adhesion molecule-1 expression in human thyroid cells in vitro and human thyroid tissue transplanted to the nude mouse in vivo: role of Graves' immunoglobulins and human thyrotropin receptor.
    Hoermann R; Spitzweg C; Poertl S; Mann K; Heufelder AE; Schumm-Draeger PM
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2048-55. PubMed ID: 9215271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study.
    Pearce SHS; Dayan C; Wraith DC; Barrell K; Olive N; Jansson L; Walker-Smith T; Carnegie C; Martin KF; Boelaert K; Gilbert J; Higham CE; Muller I; Murray RD; Perros P; Razvi S; Vaidya B; Wernig F; Kahaly GJ
    Thyroid; 2019 Jul; 29(7):1003-1011. PubMed ID: 31194638
    [No Abstract]   [Full Text] [Related]  

  • 36. Monoclonal pathogenic antibodies to the thyroid-stimulating hormone receptor in Graves' disease with potent thyroid-stimulating activity but differential blocking activity activate multiple signaling pathways.
    Gilbert JA; Gianoukakis AG; Salehi S; Moorhead J; Rao PV; Khan MZ; McGregor AM; Smith TJ; Banga JP
    J Immunol; 2006 Apr; 176(8):5084-92. PubMed ID: 16585606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alterations of Global DNA Methylation and DNA Methyltransferase Expression in T and B Lymphocytes from Patients with Newly Diagnosed Autoimmune Thyroid Diseases After Treatment: A Follow-Up Study.
    Guo Q; Wu D; Yu H; Bao J; Peng S; Shan Z; Guan H; Teng W
    Thyroid; 2018 Mar; 28(3):377-385. PubMed ID: 29336230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A patient-specific treatment model for Graves' hyperthyroidism.
    Pandiyan B; Merrill SJ; Di Bari F; Antonelli A; Benvenga S
    Theor Biol Med Model; 2018 Jan; 15(1):1. PubMed ID: 29310665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between CTLA-4 and CD28 molecule expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves' disease.
    Bossowski A; Stasiak-Barmuta A; Urban M
    Horm Res; 2005; 64(4):189-97. PubMed ID: 16220002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contrasting activities of thyrotropin receptor antibodies in experimental models of Graves' disease induced by injection of transfected fibroblasts or deoxyribonucleic acid vaccination.
    Rao PV; Watson PF; Weetman AP; Carayanniotis G; Banga JP
    Endocrinology; 2003 Jan; 144(1):260-6. PubMed ID: 12488353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.